NASDAQ$REPL
Replimune Group Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Replimune's clinical proof of principle was established with RP1 in combination with Opdivo for immune-responsive tumors, supporting registration-directed development in CSCC and anti-PD1 refractory melanoma. The pipeline progressed, and initial single agent data with RP2 for less immune-responsive tumors is expected in the fourth calendar quarter, with RP3 expected to enter the clinic by year-end. The management team was strengthened with the appointment of Andrea Pirzkall, M.D. as Chief Medical Officer. Gross proceeds of $115 million were raised through a public offering, strengthening the balance sheet and extending the cash runway to mid-2023.
Replimune Group, Inc. reported financial results for the fiscal first quarter ended June 30, 2020. Clinical proof of principle was established with RP1 in combination with Opdivo for immune-responsive tumors, supporting registration-directed development in CSCC and anti-PD1 refractory melanoma. The company raised gross proceeds of $115 million through a public offering, extending the cash runway to mid-2023.
- Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 refractory melanoma.
- Pipeline progressing; initial single agent data with RP2 for less immune-responsive tumors expected to be presented in the fourth calendar quarter with RP3 expected to enter the clinic by the year end
- Management team strengthened with the appointment of Andrea Pirzkall, M.D. as Chief Medical Officer
- Raised gross proceeds of $115 million through a public offering; strengthened balance sheet allows for additional studies and extension of cash runway to mid-2023
Headline financials
Revenue & EPS history
Replimune · Revenue · Quarterly
$0
Forward guidance
The company believes that the existing cash and cash equivalents and short-term investments, along with a limited use of debt, will enable the Company to fund additional studies and the overall operating plan to mid-2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
+3.7%
Avg return
Earnings day
+2.3%
Avg return
5 days after
-1.0%
Avg return
30 days after
58%
18 / 31 earnings
Positive
+86.3%
Q4 2026
Best reaction
-11.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +86.3% | +114.2% | — | |
| Q3 2026 | +6.0% | +11.1% | +0.9% | |
| Q2 2026 | -0.8% | +6.4% | +23.7% | |
| Q1 2026 | -0.4% | -4.5% | +15.1% | |
| Q4 2025 | +3.9% | -0.5% | +9.6% | |
| Q3 2025 | +7.3% | +9.7% | -9.3% | |
| Q2 2025 | -6.5% | -13.6% | -2.2% | |
| Q1 2025 | +4.1% | +5.8% | +12.7% | |
| Q4 2024 | +1.5% | -11.5% | +24.7% | |
| Q3 2024 | +4.6% | -3.6% | +21.7% | |
| Q2 2024 | -10.3% | -13.7% | -40.9% | |
| Q1 2024 | -7.2% | -14.2% | -7.5% | |
| Q4 2023 | +0.4% | -0.2% | +22.3% | |
| Q3 2023 | -11.2% | -13.0% | -33.6% | |
| Q2 2023 | -3.5% | -6.1% | +5.8% | |
| Q1 2023 | +0.0% | -2.6% | -8.0% | |
| Q4 2022 | +3.9% | -0.6% | +6.8% | |
| Q3 2022 | -0.7% | +0.5% | -16.4% | |
| Q2 2022 | +0.9% | +0.2% | -16.6% | |
| Q1 2022 | -11.8% | -12.9% | -9.3% | |
| Q4 2021 | +5.7% | +5.8% | +3.3% | |
| Q3 2021 | +12.8% | +7.2% | -8.2% | |
| Q2 2021 | -1.6% | -6.2% | -1.1% | |
| Q1 2021 | +14.6% | +10.2% | +7.7% | |
| Q4 2020 | +17.8% | +19.5% | +11.0% | |
| Q3 2020 | -1.6% | -1.4% | -31.3% | |
| Q2 2020 | -1.3% | -27.9% | -12.5% | |
| Q1 2020 | -0.8% | +6.3% | +18.6% | |
| Q4 2019 | +1.4% | +1.4% | -5.7% | |
| Q3 2019 | +0.9% | -2.7% | -17.5% | |
| Q2 2019 | +0.7% | +8.9% | +7.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro